<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34614271</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-0261</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular oncology</Title>
          <ISOAbbreviation>Mol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>UBE2T promotes β-catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK-dependent activation.</ArticleTitle>
        <Pagination>
          <StartPage>1694</StartPage>
          <EndPage>1713</EndPage>
          <MedlinePgn>1694-1713</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/1878-0261.13111</ELocationID>
        <Abstract>
          <AbstractText>Ubiquitin-conjugating enzyme E2T (UBE2T) has been implicated in many types of cancer including hepatocellular carcinoma (HCC). Epithelial-mesenchymal transition (EMT) process plays a fundamental role during tumor metastasis and progression. However, the molecular mechanisms underlying EMT in HCC in accordance with UBE2T still remain unknown. In this study, we showed that UBE2T overexpression augmented the oncogenic properties and specifically EMT in HCC cell lines, while its silencing attenuated them. UBE2T affected the activation of EMT-associated signaling pathways: MAPK/ERK, AKT/mTOR, and Wnt/β-catenin. In addition, we revealed that the epithelial protein complex of E-cadherin/β-catenin, a vital regulator of signal transduction in tumor initiation and progression, was totally disrupted at the cell membrane. In particular, we observed that UBE2T overexpression led to E-cadherin loss accompanied by a simultaneous elevation of both cytoplasmic and nuclear β-catenin, while its silencing resulted in a strong E-cadherin turnover at the cell membrane. Interestingly, chemical inhibition of the MAPK/ERK, AKT/mTOR, and Wnt/β-catenin signaling pathways demonstrated that the nuclear translocation of β-catenin and subsequent EMT was enhanced mainly by MAPK/ERK. Collectively, our findings demonstrate the UBE2T/MAPK-ERK/β-catenin axis as a critical regulator of cell state transition and EMT in HCC.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. Molecular Oncology published by John Wiley &amp; Sons Ltd on behalf of Federation of European Biochemical Societies.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lioulia</LastName>
            <ForeName>Elisavet</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mokos</LastName>
            <ForeName>Panagiotis</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Panteris</LastName>
            <ForeName>Emmanuel</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Botany, School of Biology, Aristotle University of Thessaloniki, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dafou</LastName>
            <ForeName>Dimitra</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-4170-0612</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Oncol</MedlineTA>
        <NlmUniqueID>101308230</NlmUniqueID>
        <ISSNLinking>1574-7891</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.23</RegistryNumber>
          <NameOfSubstance UI="C513404">UBE2T protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.23</RegistryNumber>
          <NameOfSubstance UI="D044763">Ubiquitin-Conjugating Enzymes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044763" MajorTopicYN="N">Ubiquitin-Conjugating Enzymes</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">E-cadherin</Keyword>
        <Keyword MajorTopicYN="N">EMT</Keyword>
        <Keyword MajorTopicYN="N">HCC</Keyword>
        <Keyword MajorTopicYN="N">MAPK/ERK</Keyword>
        <Keyword MajorTopicYN="N">UBE2T</Keyword>
        <Keyword MajorTopicYN="N">β-catenin</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>17</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34614271</ArticleId>
        <ArticleId IdType="pmc">PMC9019890</ArticleId>
        <ArticleId IdType="doi">10.1002/1878-0261.13111</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM &amp; Monsour HP Jr (2016) Hepatocellular carcinoma: a review. J Hepatocell Carcinoma
3, 41–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5063561</ArticleId>
            <ArticleId IdType="pubmed">27785449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang W &amp; Wei C (2020) Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis
7, 308–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7452544</ArticleId>
            <ArticleId IdType="pubmed">32884985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen C &amp; Wang G (2015) Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol
7, 1964–1970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4517155</ArticleId>
            <ArticleId IdType="pubmed">26244070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shao X, Lv N, Liao J, Long J, Xue R, Ai N, Xu D &amp; Fan X (2019) Copy number variation is highly correlated with differential gene expression: a pan‐cancer study. BMC Med Genet
20, 175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6842483</ArticleId>
            <ArticleId IdType="pubmed">31706287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou C, Zhang W, Chen W, Yin Y, Atyah M, Liu S, Guo L, Shi YI, Ye Q, Dong Q
et al. (2017) Integrated analysis of copy number variations and gene expression profiling in hepatocellular carcinoma. Sci Rep
7, 10570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5585301</ArticleId>
            <ArticleId IdType="pubmed">28874807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gurzu S, Kobori L, Fodor D &amp; Jung I (2019) Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: a review. Biomed Res Int
2019, 2962580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6855070</ArticleId>
            <ArticleId IdType="pubmed">31781608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giannelli G, Koudelkova P, Dituri F &amp; Mikulits W (2016) Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol
65, 798–808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27212245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Morales‐Ruiz M, Santel A, Ribera J &amp; Jimenez W (2017) The role of Akt in chronic liver disease and liver regeneration. Semin Liver Dis
37, 11–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28201844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrín G, Guerrero M, Amado V, Rodríguez‐Perálvarez M &amp; De la Mata M (2020) Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci
21, 1266.</Citation>
        </Reference>
        <Reference>
          <Citation>
Nwosu ZC, Piorońska W, Battello N, Zimmer AD, Dewidar B, Han M, Pereira S, Blagojevic B, Castven D, Charlestin V
et al. (2020) Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance. EBioMedicine
54, 102699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7182727</ArticleId>
            <ArticleId IdType="pubmed">32330875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu LJ, Xie SX, Chen YT, Xue JL, Zhang CJ &amp; Zhu F (2016) Aberrant regulation of Wnt signaling in hepatocellular carcinoma. World J Gastroenterol
22, 7486–7499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5011664</ArticleId>
            <ArticleId IdType="pubmed">27672271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim E, Lisby A, Ma C, Lo N, Ehmer U, Hayer KE, Furth EE &amp; Viatour P (2019) Promotion of growth factor signaling as a critical function of beta‐catenin during HCC progression. Nat Commun
10, 1909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6478918</ArticleId>
            <ArticleId IdType="pubmed">31015417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen YJ, Wu H &amp; Shen XZ (2016) The ubiquitin‐proteasome system and its potential application in hepatocellular carcinoma therapy. Cancer Lett
379, 245–252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26193663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yeom S, Jeong H, Kim SS &amp; Jang KL (2018) Hepatitis B virus X protein activates proteasomal activator 28 gamma expression via upregulation of p53 levels to stimulate virus replication. J Gen Virol
99, 655–666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29611800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kourtidis A, Lu R, Pence LJ &amp; Anastasiadis PZ (2017) A central role for cadherin signaling in cancer. Exp Cell Res
358, 78–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5544584</ArticleId>
            <ArticleId IdType="pubmed">28412244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhan T, Rindtorff N &amp; Boutros M (2017) Wnt signaling in cancer. Oncogene
36, 1461–1473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5357762</ArticleId>
            <ArticleId IdType="pubmed">27617575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Adhikary A, Chakraborty S, Mazumdar M, Ghosh S, Mukherjee S, Manna A, Mohanty S, Nakka KK, Joshi S, De A
et al. (2014) Inhibition of epithelial to mesenchymal transition by E‐cadherin up‐regulation via repression of slug transcription and inhibition of E‐cadherin degradation: dual role of scaffold/matrix attachment region‐binding protein 1 (SMAR1) in breast cancer cells. J Biol Chem
289, 25431–25444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4162148</ArticleId>
            <ArticleId IdType="pubmed">25086032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Molina‐Ortiz I, Bartolomé RA, Hernández‐Varas P, Colo GP &amp; Teixidó J (2009) Overexpression of E‐cadherin on melanoma cells inhibits chemokine‐promoted invasion involving p190RhoGAP/p120ctn‐dependent inactivation of RhoA. J Biol Chem
284, 15147–15157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2685696</ArticleId>
            <ArticleId IdType="pubmed">19293150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mao M, Zheng X, Jin B, Zhang F, Zhu L &amp; Cui L (2017) Effects of CD44 and E‐cadherin overexpression on the proliferation, adhesion and invasion of ovarian cancer cells. Exp Ther Med
14, 5557–5563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5740773</ArticleId>
            <ArticleId IdType="pubmed">29285092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang HG, Pan YW, Feng J, Zeng CT, Zhao XQ, Liang B &amp; Zhang WW (2019) TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E‐cadherin expression through the EMT pathway. Eur Rev Med Pharmacol Sci
23, 2003–2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30915743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Voutsadakis IA (2012) The ubiquitin‐proteasome system and signal transduction pathways regulating epithelial mesenchymal transition of cancer. J Biomed Sci
19, 67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3418218</ArticleId>
            <ArticleId IdType="pubmed">22827778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cai J, Culley MK, Zhao Y &amp; Zhao J (2018) The role of ubiquitination and deubiquitination in the regulation of cell junctions. Protein Cell
9, 754–769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6107491</ArticleId>
            <ArticleId IdType="pubmed">29080116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thapa P, Shanmugam N &amp; Pokrzywa W (2020) Ubiquitin signaling regulates RNA biogenesis, processing, and metabolism. BioEssays
42, e1900171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31778250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Song L &amp; Luo ZQ (2019) Post‐translational regulation of ubiquitin signaling. J Cell Biol
218, 1776–1786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6548142</ArticleId>
            <ArticleId IdType="pubmed">31000580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hormaechea‐Agulla D, Kim Y, Song MS &amp; Song SJ (2018) New insights into the role of E2s in the pathogenesis of diseases: lessons learned from UBE2O. Mol Cells
41, 168–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5881090</ArticleId>
            <ArticleId IdType="pubmed">29562734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD &amp; Dutta A (2006) UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell
23, 589–596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16916645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kelsall IR, Langenick J, MacKay C, Patel KJ &amp; Alpi AF (2012) The Fanconi anaemia components UBE2T and FANCM are functionally linked to nucleotide excision repair. PLoS One
7, e36970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3352854</ArticleId>
            <ArticleId IdType="pubmed">22615860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alpi AF, Chaugule V &amp; Walden H (2016) Mechanism and disease association of E2‐conjugating enzymes: lessons from UBE2T and UBE2L3. Biochem J
473, 3401–3419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5095918</ArticleId>
            <ArticleId IdType="pubmed">27729585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hu W, Xiao L, Cao C, Hua S &amp; Wu D (2016) UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3beta/beta‐catenin pathway. Oncotarget
7, 15161–15172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4924777</ArticleId>
            <ArticleId IdType="pubmed">26943030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hao P, Kang B, Li Y, Hao W &amp; Ma F (2019) UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma. Mol Med Rep
20, 1212–1220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6625406</ArticleId>
            <ArticleId IdType="pubmed">31173226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu LP, Yang M, Peng QZ, Li MY, Zhang YS, Guo YH, Chen Y &amp; Bao SY (2017) UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun
493, 20–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28935368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tao Y, Li R, Shen C, Li J, Zhang Q, Ma Z, Wang F &amp; Wang Z (2020) SENP1 is a crucial promotor for hepatocellular carcinoma through deSUMOylation of UBE2T. Aging (Albany NY)
12, 1563–1576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7053586</ArticleId>
            <ArticleId IdType="pubmed">31969492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wei X, You X, Zhang J &amp; Zhou C (2019) MicroRNA‐1305 inhibits the stemness of LCSCs and tumorigenesis by repressing the UBE2T‐dependent Akt‐signaling pathway. Mol Ther Nucleic Acids
16, 721–732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6535505</ArticleId>
            <ArticleId IdType="pubmed">31128423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Staal FJ, Burgering BM, van de Wetering M &amp; Clevers HC (1999) Tcf‐1‐mediated transcription in T lymphocytes: differential role for glycogen synthase kinase‐3 in fibroblasts and T cells. Int Immunol
11, 317–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10221643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suzuki K, Bose P, Leong‐Quong RY, Fujita DJ &amp; Riabowol K (2010) REAP: a two minute cell fractionation method. BMC Res Notes
3, 294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993727</ArticleId>
            <ArticleId IdType="pubmed">21067583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Franken NA, Rodermond HM, Stap J, Haveman J &amp; van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc
1, 2315–2319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17406473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Luo C, Yao Y, Yu Z, Zhou H, Guo L, Zhang J, Cao H, Zhang G, Li Y &amp; Jiao Z (2017) UBE2T knockdown inhibits gastric cancer progression. Oncotarget
8, 32639–32654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5464816</ArticleId>
            <ArticleId IdType="pubmed">28427240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang P, Guo Y, Zhao Z, Ning W, Wang H, Gu C, Zhang M, Qu Y, Zhang H &amp; Song Y (2020) UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. Aging (Albany NY)
12, 10275–10289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7346020</ArticleId>
            <ArticleId IdType="pubmed">32491994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yin H, Wang X, Zhang X, Zeng Y, Xu Q, Wang W, Zhou F &amp; Zhou Y (2020) UBE2T promotes radiation resistance in non‐small cell lung cancer via inducing epithelial‐mesenchymal transition and the ubiquitination‐mediated FOXO1 degradation. Cancer Lett
494, 121–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32590022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G
et al. (2020) Guidelines and definitions for research on epithelial‐mesenchymal transition. Nat Rev Mol Cell Biol
21, 341–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7250738</ArticleId>
            <ArticleId IdType="pubmed">32300252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun Y, Song GD, Sun N, Chen JQ &amp; Yang SS (2014) Slug overexpression induces stemness and promotes hepatocellular carcinoma cell invasion and metastasis. Oncol Lett
7, 1936–1940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049749</ArticleId>
            <ArticleId IdType="pubmed">24932263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lavoie H, Gagnon J &amp; Therrien M (2020) ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol
21, 607–632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32576977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yaeger R &amp; Corcoran RB (2019) Targeting alterations in the RAF‐MEK pathway. Cancer Discov
9, 329–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6397699</ArticleId>
            <ArticleId IdType="pubmed">30770389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dhillon AS, Meikle S, Yazici Z, Eulitz M &amp; Kolch W (2002) Regulation of Raf‐1 activation and signalling by dephosphorylation. EMBO J
21, 64–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC125807</ArticleId>
            <ArticleId IdType="pubmed">11782426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alzahrani AS (2019) PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol
59, 125–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31323288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nitulescu GM, Van De Venter M, Nitulescu G, Ungurianu A, Juzenas P, Peng Q, Olaru O, Grădinaru D, Tsatsakis A, Tsoukalas D
et al. (2018) The Akt pathway in oncology therapy and beyond (Review). Int J Oncol
53, 2319–2331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6203150</ArticleId>
            <ArticleId IdType="pubmed">30334567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K &amp; Reddanna P (2013) The paradox of Akt‐mTOR interactions. Front Oncol
3, 165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3687210</ArticleId>
            <ArticleId IdType="pubmed">23802099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yudushkin I (2020) Control of Akt activity and substrate phosphorylation in cells. IUBMB Life
72, 1115–1125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7317883</ArticleId>
            <ArticleId IdType="pubmed">32125765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sabatini DM (2017) Twenty‐five years of mTOR: uncovering the link from nutrients to growth. Proc Natl Acad Sci USA
114, 11818–11825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5692607</ArticleId>
            <ArticleId IdType="pubmed">29078414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang X &amp; Proud CG (2006) The mTOR pathway in the control of protein synthesis. Physiology (Bethesda)
21, 362–369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16990457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vilchez V, Turcios L, Marti F &amp; Gedaly R (2016) Targeting Wnt/β‐catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol
22, 823–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4716080</ArticleId>
            <ArticleId IdType="pubmed">26811628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang W, Smits R, Hao H &amp; He C (2019) Wnt/β‐catenin signaling in liver cancers. Cancers (Basel)
11, 926.</Citation>
        </Reference>
        <Reference>
          <Citation>
Jung YS &amp; Park JI (2020) Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β‐catenin and the destruction complex. Exp Mol Med
52, 183–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7062731</ArticleId>
            <ArticleId IdType="pubmed">32037398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Valenta T, Hausmann G &amp; Basler K (2012) The many faces and functions of β‐catenin. EMBO J
31, 2714–2736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3380220</ArticleId>
            <ArticleId IdType="pubmed">22617422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perugorria MJ, Olaizola P, Labiano I, Esparza‐Baquer A, Marzioni M, Marin JJG, Bujanda L &amp; Banales JM (2019) Wnt‐β‐catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol
16, 121–136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30451972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Tienderen GS, Groot Koerkamp B, IJzermans JNM, van der Laan LJW &amp; Verstegen MMA (2019) Recreating tumour complexity in a dish: organoid models to study liver cancer cells and their extracellular environment. Cancers (Basel)
11, 1706.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kirubakaran P, Kothandan G, Cho SJ &amp; Muthusamy K (2014) Molecular insights on TNKS1/TNKS2 and inhibitor‐IWR1 interactions. Mol Biosyst
10, 281–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24291818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Patel S, Alam A, Pant R &amp; Chattopadhyay S (2019) Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights. Front Immunol
10, 2872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6927425</ArticleId>
            <ArticleId IdType="pubmed">31921137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
García‐Reyes B, Witt L, Jansen B, Karasu E, Gehring T, Leban J, Henne‐Bruns D, Pichlo C, Brunstein E, Baumann U
et al. (2018) Discovery of inhibitor of Wnt production 2 (IWP‐2) and related compounds as selective ATP‐competitive inhibitors of casein kinase 1 (CK1) δ/ɛ. J Med Chem
61, 4087–4102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29630366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Landel I, Quambusch L, Depta L &amp; Rauh D (2020) Spotlight on AKT: current therapeutic challenges. ACS Med Chem Lett
11, 225–227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7073864</ArticleId>
            <ArticleId IdType="pubmed">32184947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu F, Yang X, Geng M &amp; Huang M (2018) Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B
8, 552–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6089851</ArticleId>
            <ArticleId IdType="pubmed">30109180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Geng F, Zhu W, Anderson RA, Leber B &amp; Andrews DW (2012) Multiple post‐translational modifications regulate E‐cadherin transport during apoptosis. J Cell Sci
125, 2615–2625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3706076</ArticleId>
            <ArticleId IdType="pubmed">22375065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woichansky I, Beretta CA, Berns N &amp; Riechmann V (2016) Three mechanisms control E‐cadherin localization to the zonula adherens. Nat Commun
7, 10834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4792928</ArticleId>
            <ArticleId IdType="pubmed">26960923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Curtis MW, Johnson KR &amp; Wheelock MJ (2008) E‐cadherin/catenin complexes are formed cotranslationally in the endoplasmic reticulum/Golgi compartments. Cell Commun Adhes
15, 365–378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2742162</ArticleId>
            <ArticleId IdType="pubmed">18937087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheng G, Lewis AE &amp; Meinkoth JL (2003) Ras stimulates aberrant cell cycle progression and apoptosis in rat thyroid cells. Mol Endocrinol
17, 450–459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12554771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Littler S, Sloss O, Geary B, Pierce A, Whetton AD &amp; Taylor SS (2019) Oncogenic MYC amplifies mitotic perturbations. Open Biol
9, 190136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6731591</ArticleId>
            <ArticleId IdType="pubmed">31455158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch M‐L, Camarda R
et al. (2020) MYC dysregulates mitosis, revealing cancer vulnerabilities. Cell Rep
30, 3368–3382.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7085414</ArticleId>
            <ArticleId IdType="pubmed">32160543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L &amp; Wu D (2020) UBE2T‐regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res
39, 222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7576867</ArticleId>
            <ArticleId IdType="pubmed">33087136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L
et al. (2017) Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT‐mTOR‐S6K signaling and drug responses. J Cell Sci
130, 203–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27663511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tatara T, Mukohara T, Tanaka R, Shimono Y, Funakoshi Y, Imamura Y, Toyoda M, Kiyota N, Hirai M, Kakeji Y
et al. (2018) 3D culture represents apoptosis induced by trastuzumab better than 2D monolayer culture. Anticancer Res
38, 2831–2839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29715106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takai A, Fako V, Dang H, Forgues M, Yu Z, Budhu A &amp; Wang XW (2016) Three‐dimensional organotypic culture models of human hepatocellular carcinoma. Sci Rep
6, 21174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754778</ArticleId>
            <ArticleId IdType="pubmed">26880118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D
et al. (2016) Tankyrase inhibition blocks Wnt/β‐catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res
22, 644–656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26224873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shang H, Hao ZQ, Fu XB, Hua XD, Ma ZH, Ai FL, Feng ZQ, Wang K, Li WX &amp; Li B (2018) Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway. Oncol Lett
15, 5966–5970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5858089</ArticleId>
            <ArticleId IdType="pubmed">29563999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu–Ebinger S
et al. (2014) Activation of β‐catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology
147, 690–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4143445</ArticleId>
            <ArticleId IdType="pubmed">24837480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yan C, Yang Q, Huo X, Li H, Zhou L &amp; Gong Z (2017) Chemical inhibition reveals differential requirements of signaling pathways in kras(V12)‐ and Myc‐induced liver tumors in transgenic zebrafish. Sci Rep
7, 45796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5381109</ArticleId>
            <ArticleId IdType="pubmed">28378824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bienz M (2005) beta‐Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol
15, R64–R67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15668160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hendriksen J, Jansen M, Brown CM, van der Velde H, van Ham M, Galjart N, Offerhaus GJ, Fagotto F &amp; Fornerod M (2008) Plasma membrane recruitment of dephosphorylated beta‐catenin upon activation of the Wnt pathway. J Cell Sci
121, 1793–1802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18460581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu J &amp; Liu X (2017) UBE2T silencing inhibited non‐small cell lung cancer cell proliferation and invasion by suppressing the wnt/β‐catenin signaling pathway. Int J Clin Exp Pathol
10, 9482–9488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6965922</ArticleId>
            <ArticleId IdType="pubmed">31966822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Akula SM, Abrams SL, Steelman LS, Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M &amp; McCubrey JA (2019) RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets
23, 915–929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31657972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang Z, Liu P, Wang J, Gong T, Zhang F, Ma J &amp; Han N (2015) Ubiquitin‐conjugating enzyme E2C regulates apoptosis‐dependent tumor progression of non‐small cell lung cancer via ERK pathway. Med Oncol
32, 149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25832867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jeong WJ, Ro EJ &amp; Choi KY (2018) Interaction between Wnt/β‐catenin and RAS‐ERK pathways and an anti‐cancer strategy via degradations of β‐catenin and RAS by targeting the Wnt/β‐catenin pathway. NPJ Precis Oncol
2, 5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5871897</ArticleId>
            <ArticleId IdType="pubmed">29872723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang XH, Meng XW, Sun X, Liu BR, Han MZ, DU YJ, Song YY &amp; Xu W (2011) Wnt/β‐catenin signaling regulates MAPK and Akt1 expression and growth of hepatocellular carcinoma cells. Neoplasma
58, 239–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21391741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee SK, Jeong WJ, Cho YH, Cha PH, Yoon JS, Ro EJ, Choi S, Oh JM, Heo Y, Kim H
et al. (2018) β‐Catenin‐RAS interaction serves as a molecular switch for RAS degradation via GSK3β. EMBO Rep
19, e46060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6280641</ArticleId>
            <ArticleId IdType="pubmed">30413483</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
